Last month, when Optimi Health kicked off an initial public offering of 2.5 million shares, the timing couldn’t have been better for the Vancouver-based manufacturer of psychedelic drugs. With President Donald Trump recently signing an executive order to accelerate research and ease the restrictions on psychedelics, there is unprecedented buzz around the potential of the hallucinogenic drugs to treat mental disorders.